atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.22 USD
-0.04 (-3.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATAI 1.22 -0.04(-3.17%)
Will ATAI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATAI
Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATAI
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August